Search Results | American Association for Cancer Research

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Abstract B55: Phase I/II study of the tumor‐targeting human L19TNF‐monoclonal antibody‐cytokine fusion protein in patients with advanced solid tumors

Gianluca Spitaleri, Tommaso M. De Pas, Cristina Noberasco, Leonardo Giovannoni, Hans D. Menseen, Luciano Zardi, Francesca Toffalorio, Chiara Catania, Alessandra Milani, Sabrina Boselli, Dario Neri, Filippo de Braud

Mol Cancer Ther (2009) 8 (12_Supplement): B55.

DOI: https://doi.org/10.1158/1535-7163.TARG-09-B55

Published: 10 December 2009

View article

Journal Articles

Phase I study of anti fibronectin ¹³¹I-L19-small immunoprotein (SIP): Preliminary dosimetric, pharmacokinetics (PK) and therapeutic results

Diego Tosi, Angela Coliva, Carlo Chiesa, Cristiana Sessa, Antonella Perotti, Giuseppe Capri, Marco Maccauro, Ettore Seregni, Silvia Marsoni, Monica Miani, Hans Menssen, Dario Neri, Luciano Zardi, Emilio Bombardieri, Luca Gianni

Cancer Res (2007) 67 (9_Supplement): 947.

Published: 01 May 2007

View article

Journal Articles

Immunomodulatory effects of recombinant fusion protein L19-IL2 in patients with refractory solid tumors

Filippo de Braud, Giuseppe Curigliano, Gianluca Spitaleri, Tommaso De Pas, Cristina Noberasco, Leonardo Giovannoni, Luciano Zardi, Hans Menssen, Alessandra Milani, Dario Neri

Cancer Res (2007) 67 (9_Supplement): 912.

Published: 01 May 2007

View article

Journal Articles

CIITA-Induced MHC Class II Expression in Mammary Adenocarcinoma Leads to a Th1 Polarization of the Tumor Microenvironment, Tumor Rejection, and Specific Antitumor Memory

Lorenzo Mortara, Patrizia Castellani, Raffaella Meazza, Giovanna Tosi, Andrea De Lerma Barbaro, Francesco A. Procopio, Alberto Comes, Luciano Zardi, Silvano Ferrini, Roberto S. Accolla

Clin Cancer Res (2006) 12 (11): 3435–3443.

DOI: https://doi.org/10.1158/1078-0432.CCR-06-0165

Published: 01 June 2006

View article

Journal Articles

Targeted Delivery of Tumor Necrosis Factor-α to Tumor Vessels Induces a Therapeutic T Cell–Mediated Immune Response that Protects the Host Against Syngeneic Tumors of Different Histologic Origin

Enrica Balza, Lorenzo Mortara, Francesca Sassi, Stefano Monteghirfo, Barbara Carnemolla, Patrizia Castellani, Dario Neri, Roberto S. Accolla, Luciano Zardi, Laura Borsi

Clin Cancer Res (2006) 12 (8): 2575–2582.

DOI: https://doi.org/10.1158/1078-0432.CCR-05-2448

Published: 25 April 2006

View article

Journal Articles

Synergistic Therapeutic Effects of a Tumor Targeting Antibody Fragment, Fused to Interleukin 12 and to Tumor Necrosis Factor α

Cornelia Halin, Verena Gafner, Maria Elena Villani, Laura Borsi, Alexander Berndt, Hartwig Kosmehl, Luciano Zardi, Dario Neri

Cancer Res (2003) 63 (12): 3202–3210.

Published: 15 June 2003

View article

Journal Articles

Immunoscintigraphic Detection of the ED-B Domain of Fibronectin, a Marker of Angiogenesis, in Patients with Cancer

Monica Santimaria, Giovanni Moscatelli, Giuseppe L. Viale, Leonardo Giovannoni, Giovanni Neri, Francesca Viti, Alessandra Leprini, Laura Borsi, Patrizia Castellani, Luciano Zardi, Dario Neri, Pietro Riva

Clin Cancer Res (2003) 9 (2): 571–579.

Published: 01 February 2003

View article

Journal Articles

Targeted Delivery of Tissue Factor to the ED-B Domain of Fibronectin, a Marker of Angiogenesis, Mediates the Infarction of Solid Tumors in Mice

Fredrik Nilsson, Hartwig Kosmehl, Luciano Zardi, Dario Neri

Cancer Res (2001) 61 (2): 711–716.

Published: 01 January 2001

View article

Journal Articles

Increased Binding Affinity and Valence of Recombinant Antibody Fragments Lead to Improved Targeting of Tumoral Angiogenesis

Francesca Viti, Lorenzo Tarli, Leonardo Giovannoni, Luciano Zardi, Dario Neri

Cancer Res (1999) 59 (2): 347–352.

Published: 01 January 1999

View article

Journal Articles

Adhesion of Kirsten-ras⁺ Tumor-progressing and Kirsten-ras⁻ Revertant 3T3 Cells on Fibronectin Proteolytic Fragments

Robert Radinsky, Kelly S. Flickinger, Mary A. Kosir, Luciano Zardi, Lloyd A. Culp

Cancer Res (1990) 50 (14): 4388–4400.

Published: 01 July 1990

View article

Journal Articles

Concentration of Fibronectin in Plasma of Tumor-bearing Mice and Synthesis by Ehrlich Ascites Tumor Cells

Luciano Zardi, Claudio Cecconi, Ottavia Barbieri, Barbara Carnemolla, Marina Picca, Leonardo Santi

Cancer Res (1979) 39 (9): 3774–3779.

Published: 01 September 1979

View article

NARROW

Abstract B55: Phase I/II study of the tumor‐targeting human L19TNF‐monoclonal antibody‐cytokine fusion protein in patients with advanced solid tumors

Phase I study of anti fibronectin ¹³¹I-L19-small immunoprotein (SIP): Preliminary dosimetric, pharmacokinetics (PK) and therapeutic results

Immunomodulatory effects of recombinant fusion protein L19-IL2 in patients with refractory solid tumors

CIITA-Induced MHC Class II Expression in Mammary Adenocarcinoma Leads to a Th1 Polarization of the Tumor Microenvironment, Tumor Rejection, and Specific Antitumor Memory

Targeted Delivery of Tumor Necrosis Factor-α to Tumor Vessels Induces a Therapeutic T Cell–Mediated Immune Response that Protects the Host Against Syngeneic Tumors of Different Histologic Origin

Synergistic Therapeutic Effects of a Tumor Targeting Antibody Fragment, Fused to Interleukin 12 and to Tumor Necrosis Factor α

Immunoscintigraphic Detection of the ED-B Domain of Fibronectin, a Marker of Angiogenesis, in Patients with Cancer

Targeted Delivery of Tissue Factor to the ED-B Domain of Fibronectin, a Marker of Angiogenesis, Mediates the Infarction of Solid Tumors in Mice

Increased Binding Affinity and Valence of Recombinant Antibody Fragments Lead to Improved Targeting of Tumoral Angiogenesis

Adhesion of Kirsten-ras⁺ Tumor-progressing and Kirsten-ras⁻ Revertant 3T3 Cells on Fibronectin Proteolytic Fragments

Concentration of Fibronectin in Plasma of Tumor-bearing Mice and Synthesis by Ehrlich Ascites Tumor Cells

AACR Journals

AACR Journals

This Feature Is Available To Subscribers Only